Trial reportPsychopharmacology2026
Effects of acute alcohol administration on endocannabinoids and relation to subjective effects.
Trial report in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal changes in endocannabinoids and clinical course of adolescent non-suicidal self-injury.Translational psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleHarmful alcohol use remains a significant global public health challenge. Examining variability in the acute subjective effects of alcohol and related neurobiological mechanisms may advance the understanding of susceptibility to harmful alcohol use. Research suggests the endocannabinoid (eCB) system may play an important role in mediating the reinforcing effects of alcohol. This study examined the relationship between alcohol-induced changes in eCB concentrations and the subjective psychoactive effects of acute alcohol consumption.
methodHealthy social drinkers (n = 28, aged 20-35 years) participated in a within-subjects, single-blind, placebo-controlled laboratory alcohol challenge study. Alcohol (0.6 g/kg; with 20% adjustment for women) and placebo sessions were counterbalanced. Subjective alcohol effects were assessed from self-report questionnaires administered pre- and post-dosing, including the Biphasic Alcohol Effects Scale (BAES), Drug Effects Questionnaire (DEQ), and Profile of Mood States (POMS). The eCBs, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), were assessed from blood plasma taken throughout the dosing session.
resultsAcute alcohol was associated with an overall decrease in 2-AG concentrations compared to placebo. Further, we found that a drop in 2-AG concentrations was associated with less drug 'liking' and feelings of 'friendliness', whereas under placebo conditions, a rise in 2-AG was associated with a smaller decrease in feelings of 'stimulation' (e.g., feeling energized, talkative). Alcohol did not significantly affect AEA concentrations.
conclusionOur study provides the first evidence that eCBs may contribute to individual differences in sensitivity to alcohol's reward-related mechanisms by influencing subjective experience, offering insight into the potential role of eCBs in the processes underlying harmful alcohol use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.